Vaccine maker Novavax said its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico.
Novavax Inc. says its COVID-19 vaccine appears 89% effective, based on early findings from a British study.
Side effects were mostly mild — tenderness and pain at the injection site. There were no reports of unusual blood clots or heart problems, Erck said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax Covid vaccine shows over 90 percent efficacy, drugmaker saysCompany says study of nearly 30,000 volunteers in US and Mexico shows its vaccine protects against variants and will seek authorisation by the third quarter of 2021.
Read more »
Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax Says Its COVID-19 Vaccine Is Highly Effective In Large StudyWhile demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical.
Read more »